Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma
出版年份 2012 全文链接
标题
Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma
作者
关键词
-
出版物
PHARMACOGENOMICS
Volume 13, Issue 14, Pages 1621-1633
出版商
Future Medicine Ltd
发表日期
2012-11-14
DOI
10.2217/pgs.12.142
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC).
- (2017) Benoit Beuselinck et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
- (2012) C. J. Peer et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
- (2012) T. Eisen et al. JNCI-Journal of the National Cancer Institute
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma
- (2011) Petri Bono et al. ACTA ONCOLOGICA
- Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
- (2011) Viktor Gruenwald et al. BMC CANCER
- Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
- (2011) Fotios Loupakis et al. BMC CANCER
- Levels of circulating CD45dimCD34+VEGFR2+ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
- (2011) F Farace et al. BRITISH JOURNAL OF CANCER
- Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
- (2011) Jenny J. Kim et al. CANCER
- Cancer Pharmacogenomics
- (2011) S W Paugh et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics
- (2011) Meghan Brennan et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Sunitinib in Urothelial Cancer: Clinical, Pharmacokinetic, and Immunohistochemical Study of Predictors of Response
- (2011) David J. Gallagher et al. EUROPEAN UROLOGY
- ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease
- (2011) Jean-Jacques Patard et al. EUROPEAN UROLOGY
- Current Pathology Keys of Renal Cell Carcinoma
- (2011) Ferran Algaba et al. EUROPEAN UROLOGY
- The Epidemiology of Renal Cell Carcinoma
- (2011) Börje Ljungberg et al. EUROPEAN UROLOGY
- The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma
- (2011) Summer S. Han et al. HUMAN MOLECULAR GENETICS
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
- (2011) Charles S Harmon et al. Journal of Translational Medicine
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Cancer genomics: from discovery science to personalized medicine
- (2011) Lynda Chin et al. NATURE MEDICINE
- CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients
- (2011) Nicolas Picard et al. TRANSPLANTATION
- Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
- (2011) Lee E. Moore et al. PLoS Genetics
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
- (2010) S. Patil et al. ANNALS OF ONCOLOGY
- ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
- (2010) T. Mizuno et al. ANNALS OF ONCOLOGY
- Knowledge of hereditary renal cancer syndromes
- (2010) Jesús García-Donas et al. ANTI-CANCER DRUGS
- Myelosuppression by sunitinib is flt-3 genotype dependent
- (2010) N P van Erp et al. BRITISH JOURNAL OF CANCER
- Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients
- (2010) Marie-Christine Etienne-Grimaldi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Sequential therapy in renal cell carcinoma
- (2010) Bernard Escudier et al. CANCER
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- (2010) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- EAU Guidelines on Renal Cell Carcinoma: The 2010 Update
- (2010) Börje Ljungberg et al. EUROPEAN UROLOGY
- The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer
- (2010) K.D. Steffensen et al. GYNECOLOGIC ONCOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
- (2010) Lokesh Jain et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new
- (2010) Kyle A Furge et al. LANCET ONCOLOGY
- Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3
- (2010) Mark P Purdue et al. NATURE GENETICS
- Treatment of metastatic renal cell carcinoma
- (2010) Maxine Sun et al. Nature Reviews Urology
- UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib
- (2009) Judith Meza-Junco et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation
- (2009) Daniela Kniepeiss et al. CLINICAL TRANSPLANTATION
- Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
- (2009) Nielka P. van Erp et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma
- (2009) Brian I Rini et al. LANCET
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
- (2008) Kiran Gupta et al. CANCER TREATMENT REVIEWS
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- (2008) A. M. Schultheis et al. CLINICAL CANCER RESEARCH
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions
- (2008) Magnus Ingelman-Sundberg NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now